Trials / Conditions / Recurrent Mycosis Fungoides

Recurrent Mycosis Fungoides

12 registered clinical trials studyying Recurrent Mycosis Fungoides — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungo NCT07003100	City of Hope Medical Center	—
Terminated	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogam NCT04541017	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refr NCT04074746	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Withdrawn	Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas NCT03373305	City of Hope Medical Center	Phase 1
Active Not Recruiting	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998	City of Hope Medical Center	Phase 1 / Phase 2
Terminated	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741	Mayo Clinic	Phase 1
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin NCT03278782	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT03075553	Mayo Clinic	Phase 2
Recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820	Mayo Clinic	Phase 1
Active Not Recruiting	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripher NCT03011814	City of Hope Medical Center	Phase 1 / Phase 2
Active Not Recruiting	Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymp NCT02520791	National Cancer Institute (NCI)	Phase 1
Recruiting	Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fu NCT02702310	Vanderbilt-Ingram Cancer Center	—